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Summary
Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to
prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK–cell
activation, and T/NK–cell homing through soluble and cell-surface mediators, the vasculature, and
immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells.
However, many molecular mechanisms preventing the efficacy of antitumor immunity have been
identified and can be disrupted by combination immunotherapy. Here, we examine
immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under
development to overcome them, focusing on lymphocyte traffic.
INTRODUCTION
Cancer immunotherapy is a rapidly developing field that has yielded impressive
breakthroughs. Although numerous approaches are under development, two stand out. The
use of monoclonal antibodies (mAb) blocking key inhibitory receptors of T cells has led to
robust antitumor immune response activation and has proved effective across multiple tumor
types (1). Second, robust clinical responses have been seen with the adoptive transfer of
tumor-specific autologous T cells, harvested from tumors (an approach that has been
specifically tested in melanoma) or generated ex vivo through the insertion of exogenous
receptors that recognize cancer cells, such as cloned T-cell receptors (TCR) or chimeric
antigen receptors (CAR; ref. 2). However, despite recent successes, many patients with
cancer fail to respond. In some cases, it is possible that lack of therapeutic response is due to
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a failure of effector T cells to reach into tumors. Tumors develop vascular barriers to T-cell
homing and can thus dampen the efficacy of immunotherapy.
T-CELL INFILTRATION IS IMPORTANT FOR OVERALL SURVIVAL
In tumor immunology, size matters. Key limiting factors of the tumor-containing capacity of
antitumor immune effector cells are their actual numbers, relative frequency, and functional
capabilities in tumors. The killer (effector) to target ratio is crucial for the fraction of tumor
cells eventually killed both in vitro and in vivo. Importantly, the baseline infiltration by T
lymphocytes has important prognostic implications for different types of solid tumors. Many
groups have demonstrated that the presence of intratumoral CD8+ and CD4+ T cells is
independently associated with a good clinical outcome (3). It is unclear what drives
spontaneous T-cell infiltration within tumors, but epigenetic changes and/or mutations could
control these phenotypes. In colorectal cancer, it has been shown that a T cell–based cellular
and molecular tumor profile predicts survival better than either surgical staging or histologic
evaluation for other risk factors such as invasiveness. In particular, transcriptomic footprints
in tumors denoting antigen-experienced T cells and T-cell activation have been shown to be
advantageous (4). In this line, it has been shown that response to immunotherapy is better in
melanoma patients with baseline T-cell infiltration (5). Therefore, it is quite plausible that T-
cell infiltration and circulation into tumors (as depicted in Fig. 1) can be a key limiting
factor for immunotherapy.
NK cells are infrequently seen in tumor biopsies. However, several studies have shown that
intratumoral NK cells can also be associated with increased survival (6). Thus, strategies
that would increase infiltration of NK lymphocytes into tumors would be a plausible strategy
to enhance antitumor efficacy. Such strategies would expectedly also enhance treatments
with antitumor mAbs that elicit NK cell–based antibody-dependent cell-mediated
cytotoxicity (ADCC), for example, Herceptin or cetuximab. However, NK-cell presence
may not be always beneficial, as NK cells could suppress CD8+ T-cell responses during
chronic infections (7, 8).
Unraveling the mechanisms of T and NK cell and recruitment can provide important
therapeutic targets that can be pharmacologically validated. Robust examples of targeting T-
cell trafficking come from the field of autoimmunity and transplantation, with antibodies
against VLA-4, α7β1, and pharmacologic antagonists for S1PRs. Contrary strategies aimed
at enhancing inbound leukocyte traffic to tumors hold promise for immune tumor rejection.
MOLECULAR TRICKS PLAYED BY TUMORS TO ATTRACT PROTUMOR
LEUKOCYTES AND REPRESS EFFECTOR T-CELL RESPONSES
Tumors manipulate the immune system through diverse mechanisms, shaping it to promote
tumor growth and dissemination. This is achieved by disruption of the generation of an
immune response, inhibition of antitumor T-cell activation, and blockade of effector T-cell
recruitment, and through recruitment of immunosuppressive cells.
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A primary mechanism of immune evasion is through inhibiting normal dendritic cell (DC)
activation and maturation, while promoting a tolerogenic DC phenotype. Tumors secrete a
number of factors that contribute to this role, and chief among them is VEGF-A (9). Tumor-
derived VEGF prevents DC maturation in patients and mice and impairs the generation of an
antitumor response. A growing body of evidence has also implicated a number of additional
tumor-derived factors that can disrupt normal DC functions, including TGF-β and
interleukin (IL)-10, as well as physiologic stimuli such as hypoxia and lactic acid.
An additional mechanism limiting the antitumor immune response is the deregulation of
immune-cell recruitment. Particularly, the recruitment of suppressive myeloid cells, such as
myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAM),
immature DCs, and immunosuppressive neutrophils, is a chief mechanism of
immunosuppression (10). Recruitment is mediated by diverse chemokines that are
overexpressed by tumor cells due to genetic alterations or physiologic stimuli such as
hypoxia. Tumors can also alter the chemistry of certain chemokines to preferentially recruit
myeloid cells such as the nitrosylated CCL2, which selectively recruits MDSCs to tumor
sites, while eliminating the ability to recruit CTLs and Th1 effector cells (11). Recruitment
of regulatory T cells (Treg) is an additional mechanism of immunosuppression, and under
hypoxic stress, tumors secrete the chemokine CCL28, which selectively attracts Tregs and
promotes tumor angiogenesis (12).
Upon arrival within the tumor environment, antitumor T cells face the important task of
overcoming local immunosuppression. A number of soluble and cell-surface molecules
expressed by tumors as well as resident cells, such as MDSCs, inhibit effector T-cell
functions that can control tumor growth. T-cell killing, cytokine elaboration, and survival
are all negatively affected within the tumor environment. For example, the programmed
death-1 (PD-1) receptor and its ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), are among the
most potent T-cell suppression pathways. These are only a few of the first examples of the
panoply of molecular mechanisms likely to be discovered. In this regard, it is likely that
inhibitory molecules expressed at the tumor microenvironment would ultimately deregulate
chemokine circuitries that attract Th1 cells and cytotoxic lymphocytes (CTL).
BLOCKING T-CELL ENTRANCE AND FUNCTIONS IN CANCER
Tumors exploit a number of mechanisms to limit T-cell homing and infiltration. Particularly
for patients without preexisting tumor-infiltrating lymphocytes (TIL), these are likely
effective barriers to successful immunotherapy. Below, we focus on the ways tumors disrupt
T-cell trafficking.
Disruption of T-Cell Homing by Tumors
Leukocyte trafficking across vascular endothelial barriers into tissues is highly regulated. In
nonlymphoid tissues, resting endothelial cells lining capillaries and venules are normally
refractory to leukocyte entry. Transmigration into tissue is achieved only occasionally by
monocytes and a few recirculating T lymphocytes. However, when septic or sterile
inflammation is elicited, endothelial cells, tissue-resident leukocytes, parenchymal cells, and
epithelial cells produce chemokines, which along with proteolytic fragments, as well as
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complement anaphylatoxins (e.g., C5a), attract leukocyte subsets. Extravasation of
leukocytes is elicited by gradients of chemokines expressed on endothelial cells and within
the extracellular matrix. Upon exposure to chemokines (as well as proinflammatory
cytokines or antigen), integrins expressed on activated leukocytes acquire an active
conformation conferring high affinity for their cognate ligands. A parallel event is the
induction of surface ICAM-1 and VCAM on endothelial cells, which is mediated by factors
that activate NF-κB (e.g., TNFα). LFA-1 (CD11a/CD18) and VLA-4 (α4β1) are the
principal mediators of leukocyte extravasation recognizing endothelial ICAM-1 and VCAM.
Selectins and selectin ligands mediate additional but weaker adhesive interactions, based on
lectin to carbohydrate chain recognition.
Tumors with high numbers of T cells express high amounts of established T cell–attracting
chemokines, including chemokine (C–C motif) ligand (CCL) 2, CCL3, CCL4, CCL5,
chemokine (C–X–C motif) ligand (CXCL) 9, and CXCL10 (13). The initiating events are
unclear, but the pattern of T-cell infiltration in mouse models suggests that a few T cells
infiltrate tumors initially, followed by a large influx of both specific and nonspecific T cells
(14). There are several ways in which tumors interfere with chemokine signaling. In skin
tumors, aberrant EGF receptor (EGFR)–RAS signaling has been shown to suppress the
production of CCL27, a chemokine constitutively expressed by normal keratinocytes, and
disruption of CCL27 expression in vivo prevented T-cell homing to skin tumors and
accelerated tumor outgrowth in a mouse model (15). In addition, CCL2, an important
chemokine for the recruitment of CTLs to the tumor site, undergoes nitrosylation induced by
reactive nitrogen species in the tumor microenvironment, which abrogates its ability to
attract tumor-specific CTLs (11). Furthermore, altered proteolytic processing of CXCL11,
an important chemokine recruiting CXCR3+ effector T cells, can impair binding and
signaling of the chemokine, ultimately reducing lymphocyte migration (16). Thus,
deregulation of chemokine expression is an important mechanism preventing T-cell
infiltration and homing.
The Aberrant Vasculature of Tumors
The vascular system develops through the coordinated actions of both vasculogenesis and
angiogenesis. Physiologic angiogenesis typically occurs during development and wound
healing, and proceeds through vessel destabilization, sprouting, endothelial migration, and
proliferation, followed by resolution and stabilization of the new vessel. Pathologic
angiogenesis, a key feature of tumor biology, shares many of the same processes, but it is
characterized by a failure of the resolution phase, which leads to the generation of a highly
disorganized vascular network.
Mounting experimental evidence indicates that the tumor vasculature can be a substantial
barrier to the extravasation of the tumor-reactive T cells and to the success of
immunotherapies. Although activated T cells could be documented in the periphery in
experimental models of cancer immunotherapy, they often fail to infiltrate the tumor itself
(17). The prohibitive nature of the tumor endothelium is likely maintained by the
coordinated actions of immunosuppressive, proangiogenic growth factors such as VEGF, as
well as angiogenesis-associated myeloid cells (MDSCs and TAMs) that directly suppress T-
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cell functions and promote pathologic angiogenesis (18). Under the influence of these
factors, the tumor endothelium downregulates the expression of adhesion molecules,
limiting extravasation of T cells. For instance, tumor endothelial cells can express high
levels of the endothelin B receptor (ETBR) and, under the influence of the cognate ligand
endothelin-1 produced by tumor cells, develop an “anergic” phenotype in which expression
of key homing adhesion molecules for T cells, such as ICAM-1, is deregulated (18). In a
similar vein, VEGF and basic fibroblast growth factor signaling on endothelial cells can
repress adhesion molecule expression and prevent T-cell infiltration. In addition, there is
evidence that the tumor endothelium can contribute to the composition of T-cell infiltration
in tumors, selectively allowing homing of specific lymphocyte subsets according to their
“polarization” (Th1 vs. Th2, Th17 or Treg), phenotype, or activation status.
It is emerging that the tumor vasculature can also shape the nature of T-cell infiltration in
tumors through direct immunosuppression. Endothelial cells can express a number of
mediators that suppress or kill effector lymphocytes such as TRAIL, PD-L1, PD-L2, B7-H3,
galectin-1, IL-10, TGF-β, and PGE2. Metabolic disruption of T cells through indoleamine
2,3-dioxygenase (IDO) expression and arginase-I by endothelial cells has also been
suggested, but whether these mechanisms are active in tumors is unknown. Whatever the
mechanism, it has been shown that a primary function of tumor endothelial cells is largely
immunosuppressive, maintained by tumor cells through paracrine mechanisms (19).
HOW TO MODIFY T-CELL INFILTRATION TO HELP IMMUNOTHERAPY
Despite the large number of immunosuppressive mechanisms operating in tumor
microenvironments, a large number of recent clinical successes that rely on immunotherapy
clearly indicate the power of targeting these pathways. There are presently numerous ways
to target immunosuppressive pathways and mobilize antitumor immunity in vivo or ex vivo:
(1) Effective antitumor T cells can be expanded ex vivo from natural TILs, or from T cells
transduced with exogenous cloned TCRs or CARs, and the host can be conditioned by
lymphodepletion to optimize their engraftment; (2) endogenous T cells can be effectively
activated by pharmacologic checkpoint inhibitors; (3) the vasculature can be disrupted by
low-dose metronomic chemotherapy or normalized by drugs targeting angiogenesis; (4)
soluble immunosuppressive factors, such as IDO, IL-6, IL-10, TGF-β, and PGE2, can be
individually blocked by specific pharmacologic inhibitors; (5) suppressor cells can be
depleted by specific chemotherapy drugs such as cyclophosphamide (for Tregs) or
gemcitabine (for MDSCs); (6) endogenous tumor-specific T-cell immunity can be
effectively boosted by exogenous vaccines; and (7) tumor-associated antigen-presenting
cells (APC) can be activated by specific drugs, including Toll-like receptor agonists,
whereas tumor antigens can be released in situ by immunogenic cell death induced by
specific chemotherapy drugs or radiation.
Tumors with Preexisting TILs
In tumors with preexisting TILs, one can assume that the tumor microenvironment does not
offer major barriers to T-cell homing. For such patients, the use of therapies aimed at
relieving local immunosuppression or enhancing the homing of adoptively transferred T
cells would be key. For example, the use of CAR T cells or ex vivo–expanded TILs that have
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introduced expression of homing receptors, such as CCR2 (20), could significantly enhance
the success of adoptive cell transfer (ACT) in these patients. In addition, the use of PD–PD-
L1–PD-L2 axis and/or CTLA-4 inhibitors could significantly promote antitumor immunity
in patients with preexisting TILs. For example, ipiliumab (anti–CTLA-4) has shown an
overall survival benefit in two randomized, phase III trials in patients with advanced
melanoma. The response rates were modest, between 10% and 15%, but a significant
survival advantage was observed in the treated populations. PD-1 is an additional
coinhibitory receptor expressed on activated T cells. In early clinical studies using either
anti-PD1 or anti–PD-L1 antibody, a large number of patients have demonstrated objective
clinical responses (21). There have been encouraging preclinical results with dual blockade
of PD-1 and CTLA-4 (22), and clinical data are still being collected. The fact that many
patients still do not respond to CTLA-4 and/or PD-1 blockade may suggest that additional
signals are required to effectively rescue TIL function. A variety of additional coinhibitory
(LAG-3, TIM-3, BTLA, 2B4, KLRG-1, CD160, etc.) and costimulatory receptors (CD28,
4-1BB, OX-40, GITR, etc.) have been identified. The additional blockade or agonist
stimulation of these targets could enhance immunotherapy (1).
Tumors Lacking Preexisting TILs
Tumors with preexisting TILs seem intrinsically more immunogenic and easier to approach
therapeutically, whereas tumors lacking TILs may be more complex. A prohibitive tumor
endothelial barrier is likely a primary reason why T cells may not be able to infiltrate
tumors. Proangiogenic signals can deregulate adhesive properties of the tumor endothelium
and, thus, antiangiogenesis therapy could be contributory to the activation of antitumor
immune response (18). However, the fact that VEGF inhibition has not been beneficial in
many human solid tumor types (23) indicates that combinatorial approaches will likely be
required, such as the use of VEGF inhibitors, or additional inhibitors of angiogenesis
pathways, and ACT.
Several methods to transform the tumor microenvironment so as to become infiltrated by T
cells have proved effective in mouse cancer models. Local intratumoral delivery of
cytokines, chemokines, or pathogen associated molecular patterns (PAMP) is a plausible
approach (24). Among the cytokines that best induce chemoattractants, the IL-12–IFN-γ–
CXCL10/11 axis stands out, together with type I IFN-α and IFN-β. Furthermore,
administration of radiotherapy and/or chemotherapy could feasibly alter the tumor
microenvironment by releasing danger signals from necrotic tumor cells (25).
An alternative approach would be to manipulate the tumor endothelium, allowing for the
infiltration of tumor-reactive T cells. This could be achieved through selective blockade of
known factors that limit T-cell infiltration. For instance, blockade of the endothelin receptor
ETB R leads to increased T-cell infiltration and limited tumor growth by reducing the effects
of ET-1 on adhesion molecule inhibition (17).
Activated T lymphocytes are a major source of proinflammatory cytokines and chemokines,
and these functions are among those derepressed by mAbs acting as checkpoint inhibitors.
In addition, some immunostimulatory mAbs, such as anti-CD40 and anti-41BB (CD137),
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may act directly on tumor-associated capillary vessels via the induction of adhesion
molecules and chemokines, further promoting antitumor activity (26).
It is important to consider that activated T cells in the tumor microenvironment are or may
become powerful sources of chemokines attracting sister T cells. Conceivably, once some
properly activated or derepressed T lymphocytes are behind the cancerous enemy lines, they
can recruit larger numbers of effector lymphocytes from circulation in a positive feedback
loop. Unfortunately, some of these lymphocyte-produced chemo-attractants bring Tregs and
MDSCs into the tumor tissue.
Another fascinating discovery is the fact that T lymphocytes remember the site where they
first recognized antigen and continue to express chemokine receptors and homing receptors
enabling them to recirculate through the same tissue, presumably patrolling for residual
antigen (27). This behavior is imprinted in T cells by tissue-resident DCs and is probably
maintained as a result of epigenetic regulation of gene expression. It is becoming clear that
tissues can recruit lymphocytes in a specific manner using chemokine combinations. For
example, CLA, CCR4, and CCR10 drive skin-homing lymphocytes, CCR4 and VLA-1 drive
lymphocytes to the respiratory tract, and α4β7 and CCR9 direct lymphocytes to the gut. This
phenomenon has been compared with bar coding, whereby memory T lymphocytes with the
appropriate specificities recirculate to the peripheral and lymphoid tissues in which antigen
is more likely to appear. This has profound implications for the route of vaccination with
cancer antigens (28) and for the priming of T cells to be used in adoptive transfer therapy.
CONCLUDING REMARKS
In our opinion, T-cell and NK-cell trafficking is a largely neglected strategy to enhance the
efficacy of tumor immunotherapy. As a monotherapy it may be weak, but it offers clear
potential to act synergistically. Synergy could be achieved with immunostimulatory mAbs
(anti–PD-1/PD-L1; anti–CTLA-4, anti-CD137, anti-CD40, or anti-OX40), with adoptive T-
cell therapy (with TILs or engineered lymphocytes), with cytotoxic monoclonal antibodies,
and with cancer vaccines. Next-generation cancer immunotherapy should harness the
trafficking of immune cells to malignant tissue to achieve superior cancer therapies.
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Figure 1.
Schematic representation of tumor microenvironment with leukocytes entering through
blood capillaries and exiting via afferent lymphatic vessels. Antitumor mechanisms favoring
the entrance of tumor-destroying leukocytes are depicted in green. Protumor mechanisms
based on the interference with effector and memory T-cell entrance, entrance of Tregs, and
MDSCs are represented in red. Efferent lymphatic (V) vessels control traffic of DCs
ferrying antigen cargo to draining lymph nodes and may play a vital role in recirculation of
memory T lymphocytes. dsRNA, double-stranded RNA; LPS, lipopolysaccharide; APC,
antigen-presenting cells; PAMP, pathogen associated molecular pattern; IDO, indoleamine
2,3-dioxygenase; DC, dendritic cell; MDSC, myeloid-derived suppressor cell.
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